Anti-inflammatories in Alzheimer's Disease-potential Therapy or Spurious Correlate?

Overview

Journal Brain Commun

Publisher Oxford University Press

Specialty Neurology

Date 2020 Nov 2

PMID 33134914

Citations 50

Authors

Jack Rivers-Auty

Alison E Mather

Ruth Peters

Catherine B Lawrence

David Brough

Affiliations

Soon will be listed here.

Abstract

Epidemiological evidence suggests non-steroidal anti-inflammatory drugs reduce the risk of Alzheimer's disease. However, clinical trials have found no evidence of non-steroidal anti-inflammatory drug efficacy. This incongruence may be due to the wrong non-steroidal anti-inflammatory drugs being tested in robust clinical trials or the epidemiological findings being caused by confounding factors. Therefore, this study used logistic regression and the innovative approach of negative binomial generalized linear mixed modelling to investigate both prevalence and cognitive decline, respectively, in the Alzheimer's Disease Neuroimaging dataset for each commonly used non-steroidal anti-inflammatory drug and paracetamol. Use of most non-steroidal anti-inflammatories was associated with reduced Alzheimer's disease prevalence yet no effect on cognitive decline was observed. Paracetamol had a similar effect on prevalence to these non-steroidal anti-inflammatory drugs suggesting this association is independent of the anti-inflammatory effects and that previous results may be due to spurious associations. Interestingly, diclofenac use was significantly associated with both reduce incidence and slower cognitive decline warranting further research into the potential therapeutic effects of diclofenac in Alzheimer's disease.

Citing Articles

Neuroinflammation: A Driving Force in the Onset and Progression of Alzheimer's Disease.

Long C, Fritts A, Broadway J, Brawman-Mintzer O, Mintzer J J Clin Med. 2025; 14(2.

PMID: 39860337 PMC: 11766252. DOI: 10.3390/jcm14020331.

Inflammation and DNA methylation in Alzheimer's disease: mechanisms of epigenetic remodelling by immune cell oxidants in the ageing brain.

Seddon A, MacArthur C, Hampton M, Stevens A Redox Rep. 2024; 29(1):2428152.

PMID: 39579010 PMC: 11587723. DOI: 10.1080/13510002.2024.2428152.

The Dual Role of Amyloid Beta-Peptide in Oxidative Stress and Inflammation: Unveiling Their Connections in Alzheimer's Disease Etiopathology.

Fanlo-Ucar H, Picon-Pages P, Herrera-Fernandez V, Ill-Raga G, Munoz F Antioxidants (Basel). 2024; 13(10).

PMID: 39456461 PMC: 11505517. DOI: 10.3390/antiox13101208.

MAD-microbial (origin of) Alzheimer's disease hypothesis: from infection and the antimicrobial response to disruption of key copper-based systems.

Min J, Sarlus H, Harris R Front Neurosci. 2024; 18:1467333.

PMID: 39416952 PMC: 11480022. DOI: 10.3389/fnins.2024.1467333.

dipeptides activate the NLRP3 inflammasome.

Rivers-Auty J, Hoyle C, Pointer A, Lawrence C, Pickering-Brown S, Brough D Brain Commun. 2024; 6(5):fcae282.

PMID: 39229486 PMC: 11369816. DOI: 10.1093/braincomms/fcae282.

References

Vijayaraghavan S, Darreh-Shori T, Rongve A, Berge G, Sando S, White L . Association of Butyrylcholinesterase-K Allele and Apolipoprotein E ɛ4 Allele with Cognitive Decline in Dementia with Lewy Bodies and Alzheimer's Disease. J Alzheimers Dis. 2016; 50(2):567-76. DOI: 10.3233/JAD-150750. View

Stewart W, Kawas C, Corrada M, Metter E . Risk of Alzheimer's disease and duration of NSAID use. Neurology. 1997; 48(3):626-32. DOI: 10.1212/wnl.48.3.626. View

Tilvis R, Kahonen-Vare M, Jolkkonen J, Valvanne J, Pitkala K, Strandberg T . Predictors of cognitive decline and mortality of aged people over a 10-year period. J Gerontol A Biol Sci Med Sci. 2004; 59(3):268-74. DOI: 10.1093/gerona/59.3.m268. View

Lo R, Hubbard A, Shaw L, Trojanowski J, Petersen R, Aisen P . Longitudinal change of biomarkers in cognitive decline. Arch Neurol. 2011; 68(10):1257-66. PMC: 5604752. DOI: 10.1001/archneurol.2011.123. View

in t Veld B, Ruitenberg A, Hofman A, Launer L, van Duijn C, Stijnen T . Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med. 2002; 345(21):1515-21. DOI: 10.1056/NEJMoa010178. View

Vemuri P, Lesnick T, Przybelski S, Machulda M, Knopman D, Mielke M . Association of lifetime intellectual enrichment with cognitive decline in the older population. JAMA Neurol. 2014; 71(8):1017-24. PMC: 4266551. DOI: 10.1001/jamaneurol.2014.963. View

Young A, Oxtoby N, Daga P, Cash D, Fox N, Ourselin S . A data-driven model of biomarker changes in sporadic Alzheimer's disease. Brain. 2014; 137(Pt 9):2564-77. PMC: 4132648. DOI: 10.1093/brain/awu176. View

Landi F, Cesari M, Onder G, Russo A, Torre S, Bernabei R . Non-steroidal anti-inflammatory drug (NSAID) use and Alzheimer disease in community-dwelling elderly patients. Am J Geriatr Psychiatry. 2003; 11(2):179-85. View

Dostert C, Petrilli V, van Bruggen R, Steele C, Mossman B, Tschopp J . Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science. 2008; 320(5876):674-7. PMC: 2396588. DOI: 10.1126/science.1156995. View

10.

Reines S, Block G, Morris J, Liu G, Nessly M, Lines C . Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology. 2004; 62(1):66-71. DOI: 10.1212/wnl.62.1.66. View

11.

Dempsey C, Rubio Araiz A, Bryson K, Finucane O, Larkin C, Mills E . Inhibiting the NLRP3 inflammasome with MCC950 promotes non-phlogistic clearance of amyloid-β and cognitive function in APP/PS1 mice. Brain Behav Immun. 2016; 61:306-316. DOI: 10.1016/j.bbi.2016.12.014. View

12.

. Results of a follow-up study to the randomized Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT). Alzheimers Dement. 2013; 9(6):714-23. PMC: 3823756. DOI: 10.1016/j.jalz.2012.11.012. View

13.

Pasqualetti P, Bonomini C, Forno G, Paulon L, Sinforiani E, Marra C . A randomized controlled study on effects of ibuprofen on cognitive progression of Alzheimer's disease. Aging Clin Exp Res. 2009; 21(2):102-10. DOI: 10.1007/BF03325217. View

14.

Kim Y, Seo S, Park S, Yang J, Lee J, Lee J . Protective effects of APOE e2 against disease progression in subcortical vascular mild cognitive impairment patients: A three-year longitudinal study. Sci Rep. 2017; 7(1):1910. PMC: 5432504. DOI: 10.1038/s41598-017-02046-y. View

15.

Weggen S, ERIKSEN J, Das P, Sagi S, Wang R, Pietrzik C . A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature. 2001; 414(6860):212-6. DOI: 10.1038/35102591. View

16.

Vlad S, Miller D, Kowall N, Felson D . Protective effects of NSAIDs on the development of Alzheimer disease. Neurology. 2008; 70(19):1672-7. PMC: 2758242. DOI: 10.1212/01.wnl.0000311269.57716.63. View

17.

Wattmo C, Londos E, Minthon L . Risk factors that affect life expectancy in Alzheimer's disease: a 15-year follow-up. Dement Geriatr Cogn Disord. 2014; 38(5-6):286-99. DOI: 10.1159/000362926. View

18.

Cornelius C, Fastbom J, Winblad B, Viitanen M . Aspirin, NSAIDs, risk of dementia, and influence of the apolipoprotein E epsilon 4 allele in an elderly population. Neuroepidemiology. 2004; 23(3):135-43. DOI: 10.1159/000075957. View

19.

Whitehair D, Sherzai A, Emond J, Raman R, Aisen P, Petersen R . Influence of apolipoprotein E varepsilon4 on rates of cognitive and functional decline in mild cognitive impairment. Alzheimers Dement. 2010; 6(5):412-9. PMC: 2943876. DOI: 10.1016/j.jalz.2009.12.003. View

20.

Green R, Schneider L, Amato D, Beelen A, Wilcock G, Swabb E . Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA. 2009; 302(23):2557-64. PMC: 2902875. DOI: 10.1001/jama.2009.1866. View